Madrigal Pharmaceuticals, Inc
Madrigal Pharmaceuticals is a U.S.-based commercial-stage biopharmaceutical company focused on developing and selling therapies for metabolic dysfunction-associated steatohepatitis (MASH). Its business is currently centered on Rezdiffra, an oral liver-directed therapy approved in the U.S. and launched in Germany, with the company now building a commercial footprint around that single product.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaSales of Rezdiffra in the United States and newly in Germany.
Programs that support reimbursement, affordability, and adherence.
Clinical, regulatory, and licensing activities to expand the MASH franchise.
Asiakkaat
Madrigal sells primarily to healthcare and pharmacy distribution channels that dispense Rezdiffra to eligible patients with noncirrhotic MASH and moderate-to-advanced fibrosis. Demand is driven by physicians diagnosing and treating a large underpenetrated disease population, while access depends heavily on commercial payers, government programs, and reimbursement terms.
Hepatology, gastroenterology, and other clinicians prescribe Rezdiffra for eligible MASH patients.
Health plans and PBMs buy access through formulary coverage, rebates, and contracting.
Medicare and Medicaid influence net pricing through rebates and statutory discounts.
Channel partners purchase and dispense the product into the patient market.
End users receive the therapy and often rely on affordability and co-pay support.
Strategia
Madrigal’s strategy is to maximize Rezdiffra’s value by expanding diagnosis, payer access, and patient starts in the U.S. while building an international franchise. It is also investing in post-approval studies, regulatory work, and business development to broaden the MASH opportunity and reduce dependence on a single product.
The company’s near-term value creation depends on converting a low-penetration MASH market into recurring prescriptions.
Geographic diversification can extend the product lifecycle and reduce reliance on the U.S. market.
A single-product profile creates concentration risk, so pipeline expansion is important for durability.
Maantiede
The company is headquartered in the United States and generated its first product revenue there after Rezdiffra’s 2024 FDA approval. Germany became its first international market in September 2025, and management has indicated plans to expand into additional countries over time.
Riskit
Madrigal is highly dependent on Rezdiffra, so any commercial slowdown, safety issue, or loss of approval would materially affect the business. It also faces typical biopharma risks around reimbursement, manufacturing, intellectual property, regulatory scrutiny, and the need for additional capital as it expands globally.
- Single-product concentrationVaikutus: KriittinenTodennäköisyys: Kohtalainen
Rezdiffra is the company’s only approved product and the main source of revenue.
Kohdistuu: Commercial and valuation concentration
- Regulatory approval maintenanceVaikutus: KorkeaTodennäköisyys: Kohtalainen
U.S. approval was under accelerated approval and EU approval is conditional, so post-approval data matters.
Kohdistuu: FDA/EMA follow-up studies and label maintenance
- Reimbursement and pricing pressureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Net revenue depends on rebates, chargebacks, returns, and co-pay support.
Kohdistuu: Gross-to-net deductions
- Manufacturing and supply chain relianceVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company relies on third-party manufacturers and could face delays or quality issues.
Kohdistuu: API and finished-dose supply
- MASH competitive intensityVaikutus: KeskitasoTodennäköisyys: Kohtalainen
There are many drugs in development for MASH, including large pharma competitors.
Kohdistuu: Market share and pricing
Kirjanpito
Harkinnanvaraiset erätRezdiffra revenue is recorded net of discounts, rebates, returns, and co-pay assistance.
Vaikutus: Can materially affect reported product revenue and quarterly comparability
Manufacturing costs incurred before approval were expensed to R&D rather than capitalized.
Vaikutus: Affects cost of sales and gross margin as commercial volumes scale
Clinical, licensing, and commercialization expenses require period-end estimates.
Vaikutus: Can move operating expenses between quarters
Interest on the Hercules and Blue Owl financing facilities affects financing costs.
Vaikutus: Impacts net loss and liquidity analysis
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Cadrenal Therapeutics, Inc.
CVKD · Pharmaceutical Preparations
Rigel Pharmaceuticals, Inc
RIGL · Pharmaceutical Preparations
Rigel Pharmaceuticals is a U.S.-based biotechnology company focused on therapies for hematologic disorders and cancer.
Fractyl Health, Inc
GUTS · Surgical & Medical Instruments & Apparatus
Fractyl Health is a U.S.-based metabolic therapeutics company developing device and gene-therapy approaches for obesity and type 2 diabetes.
Raphael Pharmaceutical Inc.
RAPH · Medicinal Chemicals & Botanical Products
Capricor Therapeutics, Inc
CAPR · Pharmaceutical Preparations
BioVie Inc
BIVIW · Pharmaceutical Preparations
Päivitetty: 24.9.2026